A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group

José A. Gómez-Puerta, Guillermo J. Pons-Estel, Rosana Quintana, Romina Nieto, Rosa M. Serrano Morales, Guillermina B. Harvey, Daniel Wojdyla, Marina Scolnik, Carmen Funes Soaje, Paula Alba Moreyra, Elisa Novatti, Fernando Arizpe, Guillermo A. Berbotto, Luciana González Lucero, Sabrina Porta, Nicolás Pérez, Anabella M. Rodriguez, Simone Appenzeller, Ana Carolina de Oliveira e Silva Montadon, Odirlei Andre MonticieloFernando S. Cavalcanti, Francinne Machado Ribeiro, Eduardo F. Borba, Edgard Torres dos Reis-Neto, Oscar Neira, José Miguel Chahuán, Milena Mimica, Gustavo Aroca Martínez, Gabriel J. Tobón, Gloria Vásquez, Gerardo Quintana-Lopez, Mario J. Moreno Alvarez, Miguel Ángel Saavedra, Mario Pérez Cristobal, Hilda Fragoso-Loyo, Luis M. Amezcua-Guerra, Yelitza C. González-Bello, Carlos Abud-Mendoza, Jorge A. Esquivel-Valerio, Margarita Duarte, Isabel Acosta Colman, Claudia Mora-Trujillo, Cristina Reátegui-Sokolova, Armando A. Calvo Quiroz, Roberto Muñoz-Louis, Ernesto Cairoli, Iliana Rosas, Martín Rebella, Mario H. Cardiel, Ignacio García de la Torre, Luis J. Catoggio, Graciela S. Alarcón, Bernardo A. Pons-Estel

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: After more than 20 years of sustained work, the Latin American Group for the Study of Lupus (GLADEL) has made a significant number of contributions to the field of lupus, not only in the differential role that race/ethnicity plays in its course and outcome but also in several other studies including the beneficial effects of using antimalarials in lupus patients and the development of consensus guidelines for the treatment of lupus in our region. Methods: A new generation of “Lupus Investigators” in more than 40 centers throughout Latin America has been constituted in order to continue the legacy of the investigators of the original cohort and to launch a novel study of serum and urinary biomarkers in patients with systemic lupus erythematosus. Results: So far, we have recruited 807 patients and 631 controls from 42 Latin-American centers including 339 patients with SLE without renal involvement, 202 patients with SLE with prevalent but inactive renal disease, 176 patients with prevalent and active renal disease and 90 patients with incident lupus nephritis. Conclusions: The different methodological aspects of the GLADEL 2.0 cohort are discussed in this manuscript, including the challenges and difficulties of conducting such an ambitious project.

Original languageEnglish
Pages (from-to)961203320988586
StatePublished - 2021
Externally publishedYes


  • Latin American
  • Lupus
  • biomarkers
  • lupus nephritis
  • multiethnic


Dive into the research topics of 'A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group'. Together they form a unique fingerprint.

Cite this